CoChat

Statin use after cancer diagnosis and survival among patients with cancer

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Purpose The association between statin use and cancer survival has been investigated in previous studies with conflicting findings. This study aimed to assess the association between statin use following cancer diagnosis and survival in six common cancers using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Methods Individuals aged ≥ 66 years diagnosed with prostate cancer, colorectal cancer, lung cancer, bladder cancer, pancreatic cancer, or non-Hodgkin lymphoma (NHL) from 2008 through 2017 were identified. Statin use was defined as two or more statin prescription fills after cancer diagnosis. Time-dependent Cox proportional hazard regression models were used to estimate the association between statin use and cancer-specific mortality for each cancer. Results This study included 34,618 patients with prostate cancer (median follow-up 4.0 years), 20,579 with colorectal cancer (2.9 years), 20,133 with lung cancer (1.7 years), 6,163 with bladder cancer (2.1 years), 4,538 with pancreatic cancer (0.8 years), and 3,270 with NHL (2.9 years). Statin use post-diagnosis was associated with a reduced risk of cancer-specific mortality in lung cancer (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.74-0.88) and pancreatic cancer (HR, 0.72; 95% CI, 0.59-0.87). The association was not statistically significant for prostate cancer, colorectal cancer, bladder cancer, or NHL. A dose-response relationship by duration of statin use was observed in lung cancer…

Overview

Integrity signals

Registry

Crossref · 10.1007/s10552-024-01939-4

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 63 references

Research works printed but not linked: 3

  1. Warren JL et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8):3–18
  2. Enewold L et al (2020) Updated overview of the SEER-medicare data: enhanced content and applications. J Natl Cancer Inst Monogr 2020(55):3–13
  3. Rubin DB (2009) Multiple Imputation for Nonresponse in Surveys. 2009: Wiley

Cited by

See all 5

Metadata

Authors
Guo, H., Malone, K. E., Heckbert, S. R., & Li, C. I.
Affiliations
University of Washington (US)
Corresponding author
Li, Christopher I.
Venue
Cancer Causes & Control
Published
2024-12-25
Volume
36
Issue
4
Pages
443-455
ISSN
  • 0957-5243 (ISSN-L)
  • 1573-7225
OpenAlex
W4405746232
Cited by
4
References
63
Citations by year
2026: 2 · 2025: 2
FWCI
0.80
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Cancer Causes & Control (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (T32CA09168)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
Keywords
statins, cancer-specific mortality, cancer survival, lung cancer, pancreatic cancer, prostate cancer, colorectal cancer, bladder cancer, non-Hodgkin lymphoma, statin therapy, dose-response relationship, SEER-Medicare
MeSH terms
Aged, Aged, 80 and over, Urinary Bladder Neoplasms, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Neoplasms, United States, Survival Rate, SEER Program, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statin use after cancer diagnosis and survival among patients with cancer. https://app.cochat.ai/papers/10.1007/s10552-024-01939-4
The paper
Guo, H., Malone, K. E., Heckbert, S. R., & Li, C. I. (2025). Statin use after cancer diagnosis and survival among patients with cancer. Cancer Causes & Control. https://doi.org/10.1007/s10552-024-01939-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.